65,437 trials
Rubella · Mumps · Measles
Primary: Anti-measles Virus Antibody Concentrations. — 1795.6; 1783.3 mIU/mL
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG — 31620.9 ng•h/mL
Lymphoma
Primary: Overall Response Rate (ORR) — 1 Participants
Ovarian Cancer
Primary: Objective Tumor Response — 12.5; 12.1 percentage of participants
Arthralgia · Breast Cancer · Pain
Primary: Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score — 5.3; 5.47 BPI score — p=0.58
Cannabis Use Disorder
Primary: Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements — 0.5795019; 0.5539831 ratio of errors (see OM description)
Non-Hodgkin's Lymphoma
Primary: ORR — 88; 81 percentage of patients
Central Serous Chorioretinopathy
Primary: Safety of Intravitreal Aflibercept Injection — 0; 0 adverse events
Overactive Bladder (OAB)
Primary: Number of Participants With Treatment-Related Adverse Events — 415 Participants
Hemophilia A
Primary: To Assess the Immunogenicity of Plasma Derived VWF/FVIII and rFVIII Concentrates by Determining the Frequency of Inhibitor Development in the First 50 EDs or in the…
Spinal Cord Injury
Primary: Shoulder Force
Parkinson's Disease · Mild Cognitive Impairment
Primary: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC) — 3.92; 3.48 scores on the CGIC
Cocaine Abuse · Cocaine-Related Disorders
Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines
Mantle Cell Lymphoma
Primary: Overall Response Rate — 92 percentage of patients
Healthy, No Evidence of Disease
Primary: Oxycodone Oral Clearance — 1.82; 2.04 L/min — p=>0.05